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Previewsa clearly exhausted phenotype and much
reduced ability to produce TNF and
IFN-g. In mice infected with Cl 13 the
absence of MDA5 results in a decrease
in the number of activated CD8+ T cells
and increased exhaustion compatible
with the impairment of CD4+ T cell help
induced by Cl 13 (Wang et al., 2012)
(Figure 1).
Exogenous type 1 IFN treatment of WT
or Mda5/ mice dramatically improved
the CD8+ T cell response, prevented
clonal exhaustion, and induced an early
termination of Cl 13 infection with
complete disappearance of splenic virus
load at day 32 p.i. (Wang et al., 2012)
(Figure 1). Thus, IFN treatment corrected
the deficient antiviral response in the
Mda5/ mice and also improved that of
WT mice. CD4+ T cell help was not
required in the presence of optimal levels
of IFN (Wang et al., 2012). IFN treatment
was effective when administered at day
3–4, at the time in which Cl 13-infected
mice terminate their type 1 IFN response,
earlier than observed with aggressive
strains such as Arm (Wang et al., 2012).
Treatment beyond a week p.i. was
completely ineffective. These resultsshow that early exposure of CD8+ T cells
to IFN improves their expansion and
survival and primes them for resistance
to clonal exhaustion. In addition to the
direct IFN effect on CD8+ T cells
(Kolumam et al., 2005), variation in early
virus load due to the enhanced T cell
response or the direct antiviral effect of
IFN or an effect of IFN on the crosspre-
sentation of viral antigens could also
play a role in the efficacy of the treatment.
The data presented in the three papers
in this issue not only greatly contribute to
the understanding of the role of IFN,
pDCs, and nucleic acid sensors in the
immune response to LCMV but also
provide important knowledge for the
understanding of the immune pathology
of other viral chronic infections and their
treatment.
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The recent re-emphasis on malaria eradication has made developing drugs that block transmission and
terminate latent disease critical. Most drugs do not affect the liver stages—an ability that is crucial to the latter
goal. Addressing this problem, Hoepfner et al. (2012) uncover the parasite’s lysyl-tRNA synthetase as a
druggable target.Malaria is a devastating global health
problem affecting millions of people and
claiming hundreds of thousands of lives
every year, primarily African children
younger than 5 years. Although the overall
burden of the disease peaked around
2004 and has declined in the last decade,
the statistics are still grim (Murray et al.,
2012). Recently, eradication has beenadvocated again by the Bill and Melinda
Gates Foundation and the World Health
Organization (Roberts and Enserink,
2007). The Plasmodium parasite causing
malaria is vectored between humans
through mosquito bites. Most deaths
are attributable to P. falciparum, one of
the five Plasmodium species infecting
humans, but high morbidity of P. vivax,which can cause dormant liver-stage
infections, also accounts for the enor-
mous economic burden. Current control
strategies include both therapeutic and
prophylactic chemotherapy and the
blocking of transmission using vector
control including insecticide-impregnated
bed nets. Achieving eradication would be
eased by the availability of effective drugs11, June 14, 2012 ª2012 Elsevier Inc. 555
Table 1. Molecular Target of Current Antimalarial Drugs and Their Stage of Action
Drug Target
Stage Specificity
Liver Blood
Hypnozoite Schizont
Intraerythrocytic
Parasites Sexual
Amodiaquine Hemozoin No No Yes No
Artemisinins Unclear No No Yes Yes
Atovaquone Cytochrome
bc1
No Yes Yes Yes
Chloroquine Hemozoin No No Yes No
Clindamycin Ribosomal RNA
(apicoplast)
No Yes Yes ND
Doxycycline Ribosome
(apicoplast)
No Yes Yes No
Lumefantrine Unknown No No Yes No
Mefloquine Hemozoin No No Yes Yes
Piperaquine Hemozoin No No Yes ND
Primaquine Unknown Yes Yes Yes Yes
Pyrimethamine DHFR No Yes Yes Yes
Proguanil DHFR No Yes Yes Yes
Pyronaridine Hemozoin No No Yes Yes
Quinine Hemozoin No No Yes Yes
Sulfadoxine DHPS No No Yes Yes
Tetracycline Ribosomal RNA
(apicoplast)
No Yes Yes No
DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; ND, not determined. Modified
from (Mazier et al., 2009).
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Previewsthat block transmission of the parasite
and eradicate dormant infections. In this
issue of Cell Host & Microbe, Hoepfner
et al. (2012) identified a novel druggable
target for both liver and blood stages of
the parasite, opening the door for the tar-
geted discovery of such antimalarials.
Within the human host, Plasmodium
has a complex life cycle with two major
phases: liver and blood. Subsequent to
a bite from an infectedmosquito, thePlas-
modium sporozoites migrate to the liver
and infect hepatocytes. After replicating
within the hepatocyte, the parasites
rupture the cell to release merozoites,
a stage specialized to infect erythrocytes.
However, two subspecies (P. vivax and
P. ovale) can assume a dormant state
(hypnozoites) within the liver that com-
monly lasts for months and can last for
years (White, 2011). After exiting the liver,
the parasite establishes a recurring life
cycle in the erythrocytes. During the blood
stage, some parasites will differentiate
into sexual forms that are transmitted to
the next human host. Each developmental
stage is characterized by distinct physi-
ology, and each has varying sensitivity to556 Cell Host & Microbe 11, June 14, 2012 ªmost drugs—making the discovery of a
single drug active against all stages
challenging (Wells et al., 2009).
To date, antimalarial chemotherapy
has primarily targeted the blood stages
(Table 1). Various drugs including atova-
quone, primaquine, pyrimethamine, and
the artemisinin derivatives are effective
in varying degrees against liver-stage
parasites. However, primaquine is the
only drug effective against the dormant
hypnozoites. Primaquine is poorly toler-
ated and induces hemolysis in glucose-
6-phosphatase dehydrogenase-deficient
patients, a trait commonly found in
ethnic populations in disease-endemic
countries. There is a need to develop ther-
apeutics to treat all stages of the disease
(Wells et al., 2009).
Recent phenotypic screening efforts
have identified new antimalarial chemical
scaffolds that are driving the development
of newclasses of drugs (Gamoet al., 2010;
Guiguemde et al., 2010; Meister et al.,
2011; Plouffe et al., 2008). In the current
work, Hoepfner et al. (2012) used re-
verse genomic approaches to identify
P. falciparum lysyl-tRNA synthetase as2012 Elsevier Inc.the novel druggable drug target for both
blood and liver stages for a compound
identified fromsuchphenotypicscreening.
Hoepfner et al. (2012) followed up on
previous work that identified cladosporin,
an antifungal molecule, as a potent anti-
malarial against intraerythrocytic para-
sites (Plouffe et al., 2008). The authors
demonstrated that this molecule was
equipotent against liver-stage parasites
and highly selective for the parasite in
relation to mammalian cells. Moreover,
cladosporin was equipotent against blood
stages of multidrug-resistant Plasmodium
strains. To understand their initial find-
ings, Hoepfner and colleagues sought to
discover the target of cladosporin.
The team first employed a chemical
haploinsufficiency screen by determining
the drug sensitivity of single heterozygous
knockout yeast strains (Winzeler et al.,
1999). Of the 5,803 yeast strains tested
(95% genome coverage), only the hetero-
zygous lysyl-tRNA synthetase knockout
strain (krs1/KRS1) was highly sensitive
to cladosporin. Next, a series of experi-
ments were performed to further establish
the specificity of lysyl-tRNA synthetase by
cladosporin in yeast. A transgenic yeast
strain overexpressing KRS1 was resistant
to cladosporin by 2-fold, whereas strains
overexpressing other t-RNA synthetases
remained equally sensitive to clado-
sporin. EMS-induced mutagenesis of the
wild-type yeast strain produced strains
with reduced cladosporin sensitivity that
reinforced the link to KRS1: 37 with 80%
of the clones harboring mutations in this
gene. Homology modeling studies of the
protein structure using crystal structures
from homologous human and bacteria
lysyl-tRNA synthetases predicted these
ten mutations to map to or close to the
ATP binding site of KRS1. Reintroducing
a mutated KRS1 gene into a wild-type
strain increased resistance to cladosporin
by 5-fold, leading to the conclusion that
the KRS1 gene was responsible for the
resistance phenotype.
Finally, inhibition of the malarial para-
site lysyl-tRNA (PfKrs1) by cladosporin
was investigated. Cladosporin-resistant
clones of P. falciparum were generated
by drug pressuring. The genome of these
clones was compared to the wild-type by
tiling array, which highlighted copy
number variants of PfKrs1 that were
acquired by three independent clones.
This represented the only genomic
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Previewsdifference between sensitive and resis-
tant clones. Additionally, when profiled,
none of the cladosporin-resistant clones
displayed crossresistance to other anti-
malarial drugs. Taken together, these
data point toward PfKrs1 being the unique
target of cladosporin. In subsequent test-
ing, cladosporin directly inhibited PfKrs1
in a biochemical assay but was only
weakly active toward its human counter-
part. This suggests that the cellular selec-
tivity arises mechanistically, making this
protein an attractive target for drug dis-
covery. Examining the homology model
using in silico docking suggested that cla-
dosporin might bind the ATP binding
pocket of PfKrs1; this hypothesis was
confirmed by direct competition between
cladosporin and ATP. Additionally, key
residues responsible for cladosporin
selectivity and specificity were identified
and further validated in yeast growth
assays. Finally, cladosporin was shown
to block de novo protein biosynthesis in
P. falciparum in a metabolic labeling
assay, as would be expected.
While the authors conservatively don’t
claim PfKrs1 as the only target of clado-sporin, the body of evidence they present
strongly points to PfKrs1 being the main
target of cladosporin. The target identifi-
cation strategy applied here illustrates
a successful case in which the target for
a compound identified in a phenotypic
screen can be successfully defined using
a combination of genetic and biochemical
approaches. On a broader view, these
findings validate the amino-tRNA synthe-
tases as drug targets for malaria and
potentially in related parasitic diseases
(toxoplasma, leishmania, and trypano-
some). The essential role of this target in
both liver and blood stages of malaria
represents a tremendous opportunity for
the discovery of the next generation of
antimalarials.REFERENCES
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Our view of the response to infection is limited by currentmethodologies, which provideminimal spatial infor-
mation on the systemic inflammatory response. In this issue, Attia et al. (2012) describe a cutting-edge
approach to image the inflammatory response to infection, which includes identification of host proteins in
three dimensions.The host inflammatory response to infec-
tion is a complex and highly orchestrated
process critical for defense against in-
vading microorganisms. On a molecular
and cellular level, the inflammatory re-
sponse involves acute phase proteins,
cytokines, chemokines, and other mole-
cules produced locally by activated or
damaged host cells, and many leukocyte
subsets, including T cells, mononuclearphagocytes,andgranulocytes.The inflam-
matory response is typically localized to
the infected tissues, but there are systemic
changes in host molecules, and multiple
organs can be infected. A comprehensive
understanding of the host response to
infection is an important step toward
development of therapeutic interventions
designed to treat and/or moderate the
severity of bacterial infections.There are numerous methods used
to evaluate the systemic inflammatory
response, including diagnostic hema-
tology and clinical chemistry analyses,
ELISA and Multiplex Luminex-based
assays, which can be used to quantitate
chemokine and cytokine levels, and flow
cytometry for characterization of leuko-
cytes. Such assays are typically per-
formed with blood or serum samples11, June 14, 2012 ª2012 Elsevier Inc. 557
